Neonatal Mortality in Europe & Central Asia
Country-level neonatal mortality mortality data for Europe & Central Asia. Age-standardized death rates per 100,000 population from the IHME Global Burden of Disease Study.
| # | Country | Rate |
|---|
This page presents neonatal mortality mortality data for countries in Europe & Central Asia, using age-standardized death rates per 100,000 population from the Institute for Health Metrics and Evaluation (IHME). Regional analysis reveals significant variation in disease burden between countries, reflecting differences in healthcare infrastructure, socioeconomic conditions, environmental risk factors, and public health policy implementation across Europe & Central Asia.
Neonatal mortality refers to deaths occurring within the first 28 days of life, a period of extreme physiological vulnerability as the newborn transitions from intrauterine to extrauterine existence. Approximately 2.4 million neonates die each year, accounting for nearly half of all under-five deaths globally. The three leading causes are preterm birth complications (including respiratory distress syndrome and intraventricular haemorrhage), intrapartum-related events (birth asphyxia and birth trauma), and neonatal sepsis and infections (including pneumonia, meningitis, and tetanus). Sub-Saharan Africa and South Asia together account for approximately 80% of neonatal deaths, reflecting gaps in skilled birth attendance, emergency obstetric care, and postnatal care in these regions. The first 24 hours of life carry the highest risk, with roughly one million newborns dying on their day of birth. Unlike under-five mortality, which has declined substantially, the pace of neonatal mortality reduction has been slower, meaning neonatal deaths comprise an increasingly large proportion of child deaths — a phenomenon known as the 'neonatal bottleneck' in child survival. Europe and Central Asia benefit from relatively strong health systems and high physician density, but face ageing populations, rising non-communicable disease burdens, and persistent East-West health outcome gradients. In Europe & Central Asia, neonatal mortality mortality is near global averages, though the region exhibits a marked gradient between Western European countries with low rates and Central Asian nations facing higher burdens.
Most neonatal deaths are preventable with known, affordable interventions. Antenatal corticosteroids for preterm labour, kangaroo mother care (continuous skin-to-skin contact), early initiation of breastfeeding, neonatal resuscitation training for birth attendants, clean cord care, and injectable antibiotics for neonatal sepsis together could avert an estimated 70% of neonatal deaths. Strengthening the continuum of care from pregnancy through the postnatal period — including emergency obstetric and newborn care (EmONC) at health facilities — is essential for further reductions.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for neonatal mortality in Europe & Central Asia, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Disease-specific death rates measure the number of deaths directly attributed to neonatal mortality per 100,000 people, after accounting for age structure. These rates capture both the prevalence of the condition and the likelihood of a fatal outcome once affected. In Europe & Central Asia, variation across countries may reflect differences in disease prevalence, access to treatment, diagnostic capacity, and the presence of comorbidities. Examining trends alongside health expenditure and intervention coverage helps identify where policy action has been most effective.